HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• New indications may accelerate ‘explosion’ in CAR T-cell therapy, but more education still needed
• Will CAR T cells become first-line therapy for hematologic malignancies?
• Blood clots, bleeding and cancer Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• Remote partnerships with APPs reduce access gaps Mark Hyde, PhD, PA-C
• Pembrolizumab shows promise for high-risk, BCG-unresponsive nonmuscle-invasive bladder cancer
• Gene therapy increases factor IX activity in severe hemophilia B
• Black women at higher risk for breast cancer recurrence, mortality
• Exercise during adjuvant breast cancer treatment may improve cardiovascular function
• Emapalumab shows efficacy, safety in hemophagocytic lymphohistiocytosis
• Daratumumab decreases risk for multiple myeloma progression, mortality
• Nivolumab safe, feasible with standard induction therapy for acute myeloid leukemia
• Rivaroxaban decreases VTE incidence during intervention period among patients with cancer
• Hybrid esophagectomy results in fewer major complications without compromising survival outcomes
• Durvalumab consolidation treatment cost-effective for non-small cell lung cancer
• World Trade Center responders at increased risk for head and neck cancers
• Female radiation oncologists receive smaller share of industry funding than male counterparts
• FDA approves Imbruvica-Gazyva combination for treatment-naive chronic lymphocytic leukemia
• FDA grants orphan drug designation to BL-8040 for pancreatic cancer
• FDA approves Cablivi, first treatment for acquired thrombotic thrombocytopenic purpura
• FDA approves daratumumab split-dosing regimen in multiple myeloma